Quantisnow Logo
Dashboard

Amendment: SEC Form SC 13G/A filed by Actinium Pharmaceuticals Inc. (Delaware)

$ATNM
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ATNM alert in real time by email
SC 13G/A 1 UnitedStates_13G__ActiniumPh.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Actinium Pharmaceuticals Inc (Title of Class of Securities) Common Stock (CUSIP Number) 00507W206 (Date of Event Which Requires Filing of this Statement) September 30, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, an* d for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of * the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 00507W206 (1) Names of reporting persons The Vanguard Group (2) Check the appropriate box if a member of a group (a) (see instructions) (b) X (3) SEC use only (4) Citizenship or place of organization Pennsylvania Number of shares beneficially owned by each reporting person with: (5) Sole voting power 0 (6) Shared voting power 48,600 (7) Sole dispositive power 1,567,507 (8) Shared dispositive power 57,493 (9) Aggregate amount beneficially owned by each reporting person 1,625,000 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 5.21% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: Actinium Pharmaceuticals Inc Item 1(b) Address of issuer's principal executive offices: 100 Park Avenue, 23rd Floor New York, NY 10017 Items 2(a)-2(c). Name, Address Of principal business office, and Citizenship of* persons filing: The Vanguard Group - 23-1945930 100 Vanguard Blvd. Malvern, PA 19355 2(d) Title of class of securities: Common Stock 2(e) CUSIP Number: 00507W206 Item 3. This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). Item 4. Ownership As of the close of business on September 30, 2024: (a) Aggregate amount beneficially owned: 1,625,000 (b) Percent of class: 5.21% (c) Number of shares as to which person has: 1. The Vanguard Group (a) Amount beneficially owned: 1,625,000 (b) Percent of class: 5.21% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 48,600 (iii) Sole power to dispose or to direct the disposition of: 1,567,507 (iv) Shared power to dispose or to direct the disposition of: 57,493 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following . Item 6. Ownership of More than 5 Percent on Behalf of Another Person. The Vanguard Group, Inc.'s clients, including investment companies registered u* nder the Investment Company Act of 1940 and other managed accounts, have the ri* ght to receive or the power to direct the receipt of dividends from, or the pro* ceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5* %. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reporting on by the Parent Holding Company or Control Person. Not applicable Item 8. Identification and Classification of Members of the Group Not applicable Item 9. Notice of Dissolution of Group. Not applicable Item 10. Certifications By signing below I certify that, to the best of his/her knowledge and belief, t* he securities referred to above were not acquired and are not held for the pur* pose of or with the effect of changing or influencing the control of the issuer* of the securities and were not acquired and are not held in connection with or* as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: November 12, 2024 THE VANGUARD GROUP By: /s/ Ashley Grim Name: Ashley Grim Title: Head of Global Fund Administration
Get the next $ATNM alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ATNM

DatePrice TargetRatingAnalyst
8/7/2024$16.00 → $2.00Buy → Neutral
B. Riley Securities
5/14/2024$25.00Overweight
Stephens
9/6/2023$11.60Buy
HSBC Securities
2/21/2023Outperform → Mkt Perform
William Blair
9/8/2022$20.00Overweight
Cantor Fitzgerald
8/25/2022$16.00Buy
B. Riley Securities
8/3/2021$57.00 → $45.00Buy
HC Wainwright & Co.
More analyst ratings

$ATNM
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference

    NEW YORK, March 12, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it will participate at the 37th Annual Roth Conference on March 16th to 18th. Actinium management will be in attendance during the conference and will be available for 1-on-1 meetings on March 17th and 18th. Interested investors should contact their ROTH representative or submit a registration request at Roth2025Registration. About Actinium Pharmaceuticals, Inc. Actinium is a pioneer in the devel

    $ATNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML

    Represents first ever triplet combination using targeted radiotherapy as a backbone therapy in AML with initial clinical data expected in 2H:2025Expansion into frontline setting greatly expands potential addressable patient opportunity for Actimab-ATriplet combination supported by previously completed Phase 1 trials of Actimab-A + Venetoclax and Actimab-A + CLAG-M demonstrating Actimab-A's mutation agnostic and synergistic potentialNEW YORK, March 11, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that the first clinical trial under its previously announced Cooperative Researc

    $ATNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024

    -  Aligned with FDA on operationally seamless Phase 2/3 trial for Actimab-A + CLAG-M in relapsed/refractory acute myeloid leukemia -  Actimab-A selected for National Cancer Institute's recently opened myeloMATCH precision medicines program for patients with acute myeloid leukemia and myelodysplastic syndromes -  Two Iomab-ACT INDs cleared by FDA: Commercial CAR-T trial at University of Texas Southwestern and sickle cell transplant trial at Columbia University; proof-of-concept safety and efficacy data expected in 2025 -  Actinium seeking U.S. strategic partner for Iomab-B to conduct dose optimization and head-to-head Phase 3 trial based on FDA guidance in adult patients with active relapsed

    $ATNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ATNM
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ATNM
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ATNM
 SEC Filings

See more

$ATNM
 Leadership Updates

Live Leadership Updates

See more

  • Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

    -       Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors   -       Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu

    $ATNM
    $AVTX
    $RDHL
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Coya Therapeutics Strengthens Leadership Team with Addition of Arun Swaminathan, Ph.D. as Chief Business Officer

    Dr. Swaminathan will be responsible for establishing and leading business development, leveraging his expertise in licensing, transactions, and establishing strategic collaborations within the biotechnology and pharmaceutical industries. In his two prior companies serving as Chief Business Officer, Dr. Swaminathan demonstrated strong deal making ability - At Alteogen, he executed $3.8 billion and $1.4 billion deals with two top ten global pharmaceutical companies, increasing the value of the company approximately 10-fold, from $400 million to $4 billion. At Actinium, within a year of his hiring, he executed the largest deal in their history, worth $452 million for commercial rights of

    $ATNM
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Actinium Appoints Seasoned Leader Caroline Yarbrough as Chief Commercial Officer to Spearhead Iomab-B Commercialization

    -Caroline joins Actinium from Novartis where she served as Portfolio General Manager, US Oncology-Proven commercial leadership experience spans hematology, oncology and rare diseases at Novartis, Glaxo SmithKline, Bristol Myers Squibb, ViroPharma and Merck & Co. NEW YORK, Nov. 2, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced the appointment of Caroline Yarbrough as Chief Commercial Officer. Caroline joins Actinium from Novartis where she most recently served as Portfolio General Manager, US Oncology, with full P&L responsibility of a diverse portfolio of brands and development

    $ATNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ATNM
 Financials

Live finance-specific insights

See more

  • Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024

    -  Aligned with FDA on operationally seamless Phase 2/3 trial for Actimab-A + CLAG-M in relapsed/refractory acute myeloid leukemia -  Actimab-A selected for National Cancer Institute's recently opened myeloMATCH precision medicines program for patients with acute myeloid leukemia and myelodysplastic syndromes -  Two Iomab-ACT INDs cleared by FDA: Commercial CAR-T trial at University of Texas Southwestern and sickle cell transplant trial at Columbia University; proof-of-concept safety and efficacy data expected in 2025 -  Actinium seeking U.S. strategic partner for Iomab-B to conduct dose optimization and head-to-head Phase 3 trial based on FDA guidance in adult patients with active relapsed

    $ATNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia

    -  Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of <0.0001), 22% of patients achieved dCR in the Iomab-B arm compared to 0% in the control arm -  In patients achieving 6-month dCR with Iomab-b, 1-year survival of 92% and 2-year survival of 60% was achieved; median overall survival (OS) has not been reached in these patients -  Iomab-B demonstrated significant improvement in Event Free Survival (EFS) with a Hazard Ratio = 0.22, p<0.0001 -  Iomab-B doubled 1-year survival and median overall survival compared to control arm patients who did not crossover -  Iomab-B was

    $ATNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Actinium to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings on Saturday, February 18, 2023

    -  Late-breaker presentation at 5:00 PM EST on Saturday, February 18, 2023, to feature Iomab-B SIERRA Pivotal Trial results -  Investor call at 6:00 PM EST on Saturday, February 18, 2023, to highlight full results from the Phase 3 SIERRA trial NEW YORK, Feb. 14, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies, today announced its presence at the upcoming Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) being held February 15 – 19,

    $ATNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ATNM
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more